Phreesia posted Q2 earnings of $0.03, short of the $0.10 consensus, while revenue reached $129.458 million, slightly above expectations. The company reaffirmed FY2027 revenue guidance of $510-520 million. Shares fell about 5.6% after the print as analysts raised targets to reflect potential upside, though near-term earnings misses cap enthusiasm. The mix suggests a watchful period ahead for growth trajectory and cost management.
Phreesia will announce its fourth-quarter earnings on March 30, with analysts predicting earnings of $0.07 per share and revenue growth to $126.62 million. The recent refinancing of a bridge loan to a revolving credit facility may bolster financial stability but could also raise market scrutiny post-earnings.
Phreesia will report Q3 earnings on Dec. 8. Expected earnings per share is 24 cents, up from 4 cents last year. Revenue estimate is $120.03 million, higher than $106.8 million last year. Analysts maintain bullish ratings and raise price targets significantly. Recent share price increased by 0.8% to $20.55.
Phreesia reported earnings of 1 cent, beating estimates of a 6 cent loss. Quarterly sales reached $117.255 million, surpassing expectations of $116.526 million. Phreesia confirmed FY2026 sales guidance between $472 million and $482 million. CEO announced acquisition of AccessOne to enhance healthcare receivable financing solutions. Analysts have raised price targets, indicating continued optimism despite a recent share dip.
